We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Emergence of Suicidal Ideation and Behavior During Antidepressant Pharmacotherapy

J. John Mann, MD; Shitij Kapur, MD
Arch Gen Psychiatry. 1991;48(11):1027-1033. doi:10.1001/archpsyc.1991.01810350067011.
Text Size: A A A
Published online


From making the cure of a disease more grievous than its endurance, Good Lord deliver us.— Sir Robert Hutchinson

It has recently been suggested that a selective serotonin reuptake inhibitor, fluoxetine, may trigger suicidal ideation or acts in patients receiving this drug for the treatment of depression.1 This hypothesized association is surprising because there is considerable evidence of serotonin deficiency in patients who attempt or complete suicide,2,3 and fluoxetine selectively enhances serotonergic transmission. To resolve this apparent paradox, we reviewed the biologic aspects of suicidal behavior, with special reference to the role of serotonin (5-HT) and to the evidence for the emergence of paradoxical suicidality during antidepressant treatment. Special attention was also paid to the recent literature on selective serotonin reuptake inhibitors and fluoxetine and to the research and clinical implications of these findings.

BIOLOGY OF SUICIDAL BEHAVIOR  Suicide has traditionally been regarded as an extreme response


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.